Arbutus Biopharma Corporation
ABUS
$4.31
-$0.08-1.82%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 98.68% | -95.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 98.68% | -95.07% | |||
| Cost of Revenue | -13.36% | 5.09% | |||
| Gross Profit | 24.65% | -200.15% | |||
| SG&A Expenses | 21.19% | -8.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.44% | -0.05% | |||
| Operating Income | 7.83% | -533.51% | |||
| Income Before Tax | 51.49% | -406.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 51.49% | -406.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 51.49% | -406.86% | |||
| EBIT | 7.83% | -533.51% | |||
| EBITDA | 7.84% | -530.46% | |||
| EPS Basic | 51.73% | -406.06% | |||
| Normalized Basic EPS | 8.33% | -350.00% | |||
| EPS Diluted | 51.73% | -504.00% | |||
| Normalized Diluted EPS | 8.33% | -350.00% | |||
| Average Basic Shares Outstanding | 0.30% | 0.12% | |||
| Average Diluted Shares Outstanding | 0.30% | -0.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||